$MYOK News
Last published 4y ago
- 4y agoMYOKApproval of Camzyos, Nda #214998 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 04/28/2022; Drug Name: Camzyos, Nda #214998; Active Ingredients: MAVACAMTEN; Company: Myokardia Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 214998
- 5y agoMYOKA Study of Mavacamten in Participants With HFpEF and Chronic Elevation of cTnI and/or NT-proBNP - NCT04766892ClinicalTrials.govFrequency and severity of treatment-emergent adverse events, adverse events of special interest, and serious adverse events., Mavacamten effect on cTnI levels (at rest), Mavacamten effect on NT-proBNP levels (at rest)
- 5y agoMYOKMyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of MavacamtenGlobeNewswireEXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure --...
- 5y agoMYOKMyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020GlobeNewswireECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from...
- 6y agoMYOKMyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic CardiomyopathyGlobeNewswireBRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry...
- 6y agoMYOKMyoKardia Reports Third Quarter 2020 Financial ResultsGlobeNewswireBRISBANE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020. Recent Clinical Program...
- 6y agoMYOKBMYBristol-Myers Raises 2020 Earnings Guidance on Covid RecoveryBloombergBristol-Myers Squibb Co. raised its full-year earnings forecast as better-than-expected sales of drugs treating conditions including cancer beat analyst estimates in the third quarter.
- 6y agoBMYEXELBLUEMYOKBristol Myers Squibb Reports Third Quarter 2020 Financial ResultsBusiness WireNEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2020, which reflect strong product sales, continued pipeline advancement and robust operating performance.
- 6y agoMYOKMyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants ProgramGlobeNewswireBRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive...
- 6y agoBMYMYOKBristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting PeriodBusiness WireNEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 pe ...
- 6y agoMYOKMyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020GlobeNewswireBRISBANE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the upcoming presentation of clinical and non-clinical data related to mavacamten, MyoKardia’s...
- 6y agoBSTCCITMYOKPEMoore Kuehn Encourages MYOK, BSTC, CIT, and PE and Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
- 6y agoARAMRMYOKMoore Kuehn Encourages ARA, EIDX, MR, and MYOK Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoBMYMYOKBristol-Myers gets 'potentially revolutionary medicine' in MyoKardia deal, CEO saysCNBC"MyoKardia is an important company because they developed a really interesting approach to the treatment of cardiovascular disease," Bristol-Myers Squibb CEO Giovanni Caforio said.
- 6y agoREGNCRWDAMCDKNG+5Stocks making the biggest moves midday: Regeneron, CrowdStrike, AMC Entertainment and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 6y agoMYOKBMYEIDXBBIO+11Stocks making the biggest moves in the premarket: MyoKardia, Eidos Therapeutics, DraftKings & moreCNBCThe stocks making the biggest moves in premarket trading include MyoKardia, Eidos Therapeutics, DraftKings, and more.
- 6y agoMYOKBMYBristol-Myers to Buy Heart-Drug Maker MyoKardia for $13 BillionBloombergBristol-Myers Squibb Co. will buy MyoKardia Inc. in a deal valued at $13.1 billion in cash to expand its offering of heart drugs.
- 6y agoBMYMYOKBristol-Myers to buy heart drugs developer MyoKardia for about $13 billionCNBCU.S. drugmaker Bristol-Myers Squibb said on Monday it would buy heart drugs developer MyoKardia for about $13 billion.
- 6y agoBMYMYOKBristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in CashBusiness WireNEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close ...
- 6y agoMYOKExploratory Study of MYK-491 in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants - NCT04572893ClinicalTrials.govFrequency and severity of treatment-emergent adverse events and serious adverse events.
- 6y agoMYOKMyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated CardiomyopathyGlobeNewswireBRISBANE, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv...
- 6y agoMYOKMyoKardia to Participate in September Investor ConferencesGlobeNewswireBRISBANE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences: Citi’s 15th Annual BioPharma...
- 6y agoMYOKMyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic CardiomyopathyGlobeNewswireEXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet Presentation Expands on Positive Topline Results Showing Early, Sustained...
- 6y agoMYOKMyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater ChinaGlobeNewswireNear-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos...
- 6y agoMYOKData from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020GlobeNewswireBRISBANE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial...
- 6y agoMYOKMyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewswireBRISBANE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare...
- 6y agoMYOKMyoKardia Reports Second Quarter 2020 Financial ResultsGlobeNewswireBRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020. “The second quarter of 2020 was one...
- 6y agoMYOKCORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of MavacamtenGlobeNewswireBRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (Nasdaq: MYOK), please note that the second quote by Jeffrey...
- 6y agoMYOKMyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of MavacamtenGlobeNewswireBRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. VALOR-HCM will enroll...
- 6y agoMYOKMyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020GlobeNewswireBRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020....
- 6y agoMYOKMyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic CardiomyopathyGlobeNewswireBRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to...
- 6y agoMYOKMyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic CardiomyopathiesGlobeNewswireBRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for...
- 6y agoMYOKMyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic CardiomyopathiesGlobeNewswireBRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for...
- 6y agoMYOKMyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate SecretaryGlobeNewswireBRISBANE, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins...
- 6y agoMYOKMyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association DiscoveriesGlobeNewswire-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- BRISBANE, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that data from...
- 6y agoWFCBLKPNCQTWO+8Big Companies Cashed In on Stock Rally With Flood of OfferingsBloombergThe seven-week rally that pushed stocks higher by 30% was a great time to be selling, if you were corporate America.
- 6y agoMYOKMyoKardia Announces Pricing of Public Offering of Common StockGlobeNewswireBRISBANE, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of...
- 6y agoMYOKMyoKardia Announces Proposed Public Offering of Common StockGlobeNewswireBRISBANE, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of...
- 6y agoMYOKMyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic CardiomyopathyGlobeNewswireHighly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo Mavacamten Well Tolerated; Safety Results Comparable to Placebo U.S. Regulatory...
- 6y agoJPMAMGNMYOKMyoKardia Surges After Heart Drug Clears Late-Stage HurdleBloombergMyoKardia Inc. jumped on Monday after its experimental treatment for a rare heart condition met its primary goal and all secondary targets in a key study, delivering a win for the now $4.7 billion drugmaker.
- 6y agoMYOKNew patent application published for: 4-Methylsulfonyl-Substituted Piperidine Urea CompoundsUS Patent Applications (USPTO)
- 6y agoMYOKMyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy PatientsGlobeNewswireMAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in...
- 6y agoMYOKMyoKardia Provides Clinical Trial Update in the Context of the COVID-19 PandemicGlobeNewswireBRISBANE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 (coronavirus)...
- 6y agoMYOKData from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of CardiologyGlobeNewswireBRISBANE, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a...
- 6y agoMYOKMyoKardia Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewswireBRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. “MyoKardia...
- 6y agoMYOKMyoKardia to Present at Evercore ISI 2nd Annual HealthCONx ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at...
- 7y agoMYOKMyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of MavacamtenGlobeNewswireAchieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo...
- 7y agoMYOKMyoKardia Announces 48-week Data from PIONEER-OLE Study of MavacamtenGlobeNewswireMavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s...
- 7y agoMYOKMyoKardia Reports Third Quarter 2019 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the quarter ended September 30, 2019. “As we look across the...
- 7y agoMYOKMyoKardia to Present at 2019 Cantor Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will participate in a fireside chat at...